$26.65 Million in Sales Expected for ADMA Biologics, Inc. (NASDAQ:ADMA) This Quarter

Wall Street brokerages expect that ADMA Biologics, Inc. (NASDAQ:ADMA – Get Rating) will report $26.65 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for ADMA Biologics’ earnings. The lowest sales estimate is $26.50 million and the highest is $26.80 million. ADMA Biologics reported sales of $16.05 million in the same quarter last year, which indicates a positive year over year growth rate of 66%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that ADMA Biologics will report full year sales of $124.20 million for the current year, with estimates ranging from $123.40 million to $125.00 million. For the next financial year, analysts forecast that the business will post sales of $185.90 million, with estimates ranging from $171.50 million to $200.30 million. Zacks’ sales averages are an average based on a survey of analysts that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA – Get Rating) last issued its quarterly earnings data on Thursday, March 24th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. ADMA Biologics had a negative net margin of 88.51% and a negative return on equity of 61.23%. The firm had revenue of $26.38 million for the quarter, compared to analyst estimates of $26.00 million. During the same quarter in the previous year, the business posted ($0.20) EPS.

A number of equities analysts have commented on ADMA shares. StockNews.com started coverage on shares of ADMA Biologics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics currently has a consensus rating of “Buy” and an average target price of $5.00.

Several large investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ADMA Biologics during the 1st quarter valued at about $40,000. EWG Elevate Inc. bought a new stake in shares of ADMA Biologics during the 1st quarter valued at about $183,000. BlackRock Inc. grew its position in shares of ADMA Biologics by 73.3% during the 4th quarter. BlackRock Inc. now owns 4,075,591 shares of the biotechnology company’s stock valued at $5,746,000 after buying an additional 1,724,224 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $125,000. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of ADMA Biologics by 795.6% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 680,684 shares of the biotechnology company’s stock valued at $960,000 after buying an additional 604,684 shares during the last quarter. 32.16% of the stock is owned by institutional investors and hedge funds.

Shares of ADMA stock opened at $1.99 on Monday. ADMA Biologics has a 12 month low of $1.01 and a 12 month high of $2.63. The company has a current ratio of 6.87, a quick ratio of 2.77 and a debt-to-equity ratio of 0.72. The company’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $1.51.

About ADMA Biologics (Get Rating)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

See Also